Abstract：Objective To study the applicability of ciprofol combined with nalbuphine in painless gastroenteroscopy on elderly patients. Methods A total of 121 elderly patients who were scheduled to undergo painless gastroscopic diagnosis and treatment (including biopsy and polypectomy) in the Civil Aviation General Hospital from May 2021 to December 2021 were selected and randomly divided into two groups: ciprofol combined with nalbuphine (group A, 61 cases), and propofol combined with nalbuphine (group B, 60 cases). The patients in the two groups were treated at the same dose (nalbuphine: 0.1 mg/kg, propofol or ciprofol: 0.12-0.16 ml/kg) and at the same speed for anesthesia induction. After ‘Modified Observer’s Assessment of Alertness/Sedation Scale (MOAAS) of the subjects≤ 1, the diagnosis and treatment procedure of bidirectional endoscopy was started. The rapid in-duction time, awaken time, induced dose, number of drug additions and additional doses, total dosage, post anesthesia care time and adverse events (injection pain, entry cough reaction, low heart rate, hypotension, respiratory depression, nausea and vomiting) were observed in the two groups. Results There were no cases of diagnosis and treatment failure in both groups, with no significant difference between the two groups in rapid induction time, number and dose of drug addition, total drug dosage, and post anesthesia care time. No statistically significant changes in variation tendency of heart rate, mean arterial pressure and pulse oxygen saturation between the two groups, showing a time change trend (F=66.700, P<0.05;F=64.708, P<0.05;F=15.634, P<0.05),with no interaction between times and groups (F=1.946,P>0.05;F=0.980,P>0.05;F=1.586,P>0.05). Compared with group B, the incidence of injection pain, entry cough reaction, hypotension, bradycardia and respiratory depression in group A were significantly reduced (P<0.05 ). There was no significant difference in the incidence of nausea and vomiting between the two groups (P>0.05 ). Conclusions The effect of ciprofol combined with nalbuphine in elderly patients with painless gastroenteroscopy is comparable to that of propofol combined with nalbuphine. However, the incidence of adverse reactions, such as injection pain, entry cough reaction, respiratory depression, hypotension and bradycardia, was lower.
Chidambaran V, Costandi A, D’Mello A. Propofol: a review of its role in pediatric anesthesia and sedation [J]. CNS Drugs, 2015,29(7):543-563.
[3]
Zhang W, Zhu Z, Zheng Y. Effect and safety of propofol for sedation during colonoscopy: a meta-analysis [J].J Clin Anesth,2018,12(51):10-18.
[4]
Bian Y, Zhang H, Ma S, et al. Mass balance, pharmacokinetics and pharmacodaynamics of intravenous HSK-3486, a novel anaesthetic, administered to healthy sub-jects [J].Br J Clin Pharmacol,2021,87(1):93-105.
[5]
Teng Y, Ou M, Wang X, et al. Efficacy and safety of ci-profol for the sedation/anesthesia in patients undergoing colonoscopy: Phase II a and II b multicenter clinical trials [J]. Eur J Pharm Sci,2021,164:105904.
[6]
Wang X, Wang X, Liu J, et al. Effects of ciprofol for the induction of general anesthesia in patients scheduled for elective surgery compared to propofol: aphase-3, multicenter, randomized, double-blind, comparative study [J].Eur Rev Med Pharmacol Sci,2022,26(5):1607-1617.
[7]
Deng C, Wang X, Zhu Q, et al. Comparison of nal-buphine and sufentanil for colonoscopy: a ran-do-mized controlled trial [J]. PLoS One, 2017,12(12): e0188901.
[8]
ASGE Standards of Practice Committee, Early D S, Lightdale J R, et al. Guidelines for sedation and anes-the-sia in GI endoscopy [J]. Gastrointest Endosc,2018,87(2):327-337.
[9]
Pastis N J, Hill N T, Yarmus L B, et al. Correlation of vital signs and depth of sedation by Modified Observer’s Assessment of Alertness and Sedation (MOAA/S) Scale in bronchoscopy [J].J Bronchol Intern Pu, 2022,29(1):54-61.
[10]
Hanazaki M, Jones K A, Warner D O. Effects of intravenous anesthetics on Ca2+ sensitivity in canine tracheal smooth muscle [J]. Anesthesiology, 2000,92(1):133-139.
[11]
Ouédraogo N, Marthan R, Roux E. The effects of pro-pofol and etomidate on airway contractility in chronic-ally hypoxic rats [J]. Anesth Analg, 2003,96(4):1035-1041.
[12]
Ramsay M A, Newman K B, Jacobson R M, et al. Se-dation levels during propofol adminis-tration for out-patient colonoscopies [J]. Proc (Bayl Univ Med Cent), 2014,27(1):12-15.
[13]
Hu C, Ou X, Teng Y, et al. Sedation effects produced by a ciprofol initial infusion or bolus dose followed by continuous maintenance infusion in healthy subjects: a phase 1 trial [J]. Adv Ther,2021,38(11):5484-5500.
[14]
Li X, Yang D, Li Q, et al. Safety, pharmacokinetics and pharmacodynamics of a single bolus of the γ-aminobutyric acid (GABA) receptor potentiator HSK-3486 in healthy chinese elderly and non-elderly [J]. Front Pharmacol, 2021,27(12):735700.
Singla B, Malde A D. A prospective observational study of injection pain in children with medium plus long chain triglyceride and long chain triglyceride propofol premixed with lignocaine [J]. Indian J Anaesth, 2018, 62(3):214-218.
[18]
Desousa K A. Pain on propofol injection: causes and remedies [J].Indian J Pharmacol,2016,48(6):617-623.
[19]
Li J, Wang X, Liu J, et al. Comparison of ciprofol (HSK3486) versus propofol for the induction of deep sedation during gastroscopy and colonoscopy procedures: A multi-centre, non-inferiority, randomized, controlled phase 3 clinical trial [J].Basic Clin Pharmacol, 2022,131(2):138-148.
Liao J, Li M, Huang C, et al. Pharmacodynamics and pharmacokinetics of HSK3486, a novel 2,6 disubsti-tuted phenol derivative as a general anesthetic[J]. Front Pharmacol,2022,13:836791.
[24]
Luo Z, Tu H, Zhang X, et al. Efficacy and safety of HSK3486 for anesthesia/sedation in patients undergoing fiberoptic bronchoscopy: a multicenter, double-blind, propofol-controlle, randomized, phase 3 study[J]. CNS Drugs, 2022,36(3):301-313.
2023, Vol. 34 
